License and supply agreement with Genuine Health
RNS & Investor News
09 October 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that Stephen O'Hara, Chief Executive, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments (TPI) Ltd and Vox Markets.
The event will be held on Thursday, 15 October 2020 at 2pm. To access the event, please register your interest at https://voxmarkets.brand.live/c/optibiotix-health-plc-investor-presentation
No new price-sensitive information will be disclosed as part of the presentation.
OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Walbrook PR Ltd
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than sixty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The current areas of focus for the business include obesity, cardiovascular health, diabetes, digestive health, and health and wellbeing.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020